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ABSTRACT: 
Background: Necrotizing enterocolitis (NEC) continues to be a morbid surgical 
condition among preterm infants.  Novel therapies for this condition are desperately 
needed.  Hydrogen sulfide (H2S) is an endogenous gasotransmitter that has been found 
to have beneficial properties.  We therefore hypothesized that intraperitoneal injection of 
various H2S donors would improve clinical outcomes, increase intestinal perfusion, and 
reduce intestinal injury in an experimental mouse model of necrotizing enterocolitis.  
Methods:  NEC was induced in five-day-old mouse C57BL/6 mouse pups through 
maternal separation, formula feeding, and intermittent hypoxic and hypothermic stress. 
The control group (n=10) remained with their mother and breastfed ad lib.  Experimental 
groups (n=10 / group) received intraperitoneal injections of phosphate buffered saline 
(PBS) vehicle or one of the following H2S donors: (1) GYY4137, 50 mg/kg daily; (2) 
Sodium sulfide (Na2S), 20 mg/kg three times daily; (3) AP39, 0.16 mg/kg daily.  Pups 
were monitored for weight gain, clinical status, and intestinal perfusion via 
transcutaneous Laser Doppler Imaging (LDI).  After sacrifice on day nine, intestinal 
appearance and histology were scored and cytokines were measured in tissue 
homogenates of intestine, liver, and lung.  Data were compared with Mann-Whitney and 
p<0.05 was considered significant. 
Results:  Clinical score and weight gain were significantly improved in all three H2S-
treated groups as compared to vehicle (p<0.05 for all groups).  Intestinal perfusion of 
the vehicle group was 22% of baseline while the GYY4137 group was 38.7% 
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(p=0.0103), Na2S was 47.0% (p=0.0040), and AP39 was 43.0% (p=0.0018).  The 
vehicle group had a median histology score of 2.5, while the GYY4137 group’s was 1 
(p=0.0013), Na2S was 0.5 (p=0.0004), and AP39 was 0.5 (p=0.0001).  Cytokine 
analysis of the intestine of the H2S-treated groups revealed levels closer to breastfed 
pups as compared to vehicle (p<0.05 for all groups). 
 
Conclusion:  Intraperitoneal administration of H2S protects against development of 
NEC by improving mesenteric perfusion, and by limiting mucosal injury and altering the 
tissue inflammatory response.  Further experimentation is necessary to elucidate 
downstream mechanisms prior to clinical implementation. 
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INTRODUCTION: 
Necrotizing enterocolitis (NEC) is the leading cause of morbidity and mortality 
from gastrointestinal disease in the premature neonatal population.  Incidence has been 
estimated to vary from 12% to 20% of preterm infants, with mortality as high as 40% of 
those affected [1-4]. Despite NEC being the most common acquired gastrointestinal 
emergency among neonates, relatively little advancement has been made in available 
medical therapies over the last few decades.  Surgical resection of necrotic bowel is 
required in up to 50% of cases [5].  Morbidities are significant, including intestinal 
stricture and short bowel syndrome as well as growth retardation and 
neurodevelopmental delay [3].  Therefore, a novel medical therapy for this condition is 
desperately needed.   
One recently appreciated therapy for ischemic tissue injury has been hydrogen 
sulfide gas (H2S).  Recently lauded alongside nitric oxide and carbon monoxide as one 
of the three major gasotransmitters, it has been found to have anti-apoptotic, 
antioxidant, anti-inflammatory, and vasodilatory properties [6].  Though many cells 
produce it endogenously, it can also be applied exogenously with similar effects.  In 
animal models, H2S administration has been shown to provide protection against 
ischemic injury in the myocardium and brain [4, 7-9].  In mouse studies of intestinal 
ischemia and reperfusion, H2S was applied directly to the ischemic bowel resulting in 
improved intestinal perfusion and decreased histologic injury secondary to the insult [4].  
Additionally, Li et all has demonstrated in vitro protection in intestinal epithelial cells [10] 
H2S exists in its native form as a gas, but various substances act as H2S donors 
in aqueous solution.  These can be classified further into inorganic sulfide salts and 
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synthetic molecules.  Sodium hydrosulfide (NaHS) and sodium sulfide (Na2S) are the 
two most commonly used sulfide salts, and are often sold in their hydrated forms.  Two 
frequently used synthetic molecules are GYY4137 (morpholin-4-ium 4-
methoxyphenyl(morpholino) phosphinodithioate) and AP39 ((10-oxo-10-(4-(3-thioxo-3H-
1,2-dithiol-5yl)phenoxy)decyl) triphenylphosphonium bromide) [11].  These are both 
relatively large molecules that produce hydrogen sulfide at a consistent rate over time, 
leading to stable concentrations in aqueous solution [12, 13].  It is thought that AP39 
acts specifically on the mitochondria, while GYY4137 is more generalized [14].  All of 
these donors have been used in animal experiments without prohibitive adverse effects 
[12, 13, 15]. 
NEC is characterized not only by intestinal injury, but also dyscrasias in local and 
systemic inflammatory cytokine cascades.  Interleukin 6 (IL-6), typically thought of as an 
acute phase reactant, has both inflammatory and anti-inflammatory properties, and may 
act in a protective manner against intestinal injury [16, 17].  Interleukin 1 (IL-1), 
another acute phase reactant, is produced by many cell types, including the 
endothelium, in response to stress [18].  Meanwhile, a variety of angiogenic growth 
factors, such as vascular endothelial growth factor (VEGF), are released by the 
endothelium to circumvent hypoxic injury [19].  Additionally, interleukin 12 (IL-12) 
released by the mucosa is thought to be directly related to bacterial clearance and 
mucosal permeability and therefore is an important marker in experimental NEC [20].  
These four signaling molecules are some of the many that are affected in experimental 
NEC. 
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Development of NEC is certainly multifactorial, but one contributor seems to be 
intestinal ischemia and necrosis [3].  Because of this, it is plausible that H2S donors 
would be beneficial for the treatment of NEC.  We therefore hypothesized that 
intraperitoneal injection of H2S donors would improve clinical outcomes, increase 
intestinal perfusion, and reduce intestinal injury in an experimental mouse model of 
necrotizing enterocolitis.   
 
MATERIALS AND METHODS 
Experimental NEC Model: 
          Indiana University Institutional Animal Care and Use Committee approved the 
experimental protocol and animal use.  We used a previously well published and 
validated model of experimental NEC [21, 22].  C57BL/6 mouse pups (bred in house 
from adult mice obtained from Jackson Labs, Bar Harbor, ME) were permanently 
separated from their mother on postnatal day (P) five.  They were housed in a neonatal 
incubator from P5 to P9 with humidity 40% and temperature 32°C.  The control group 
(n=10) remained with their mother and breastfeed ad libitum.  Experimental groups 
(n=10 per group) were gavage fed with a 2 French catheter three times daily with 
hyperosmolar formula.  Formula was prepared using 4g of Esbilac canine supplement 
and 6g Similac in 20 mL of nanopure filtered water (Barnstead Nanopure, APS Water 
Services Inc., Van Nuys, CA).  Formula was discarded and prepared fresh every 48 
hours.  Animals were fed 300 kcal/kg/day and all feeds were supplemented with 8 
mg/kg lipopolysaccharide (lipopolysaccharides from Escherichia coli O111:B4, Sigma-
Aldrich Company LLC, Dorset, UK).  Before each feed, pups were placed in a chamber 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
with 5% O2 and 95% N2 for 10 minutes.  After the morning and evening feed, pups were 
placed in the 4°C refrigerator for 10 minutes.   Mice who died less than 24 hours into the 
protocol were excluded, as their death was more likely due to causes other than NEC.  
Any animal whose tissue was liquefied or unusable for histologic evaluation (i.e. died 
overnight and discovered hours later) was excluded completely from evaluation.  Other 
animals that died during the study but were identified immediately were still included in 
analysis for all data points.   
 
H2S-donor Administration: 
          Before hypoxic stress, experimental groups received intraperitoneal injections of 
phosphate buffered saline (PBS) vehicle or one of the following H2S donors in PBS 
solution: (1) GYY4137, 50 mg/kg daily; (2) Na2S, 20 mg/kg three times daily; (3) AP39, 
0.160 mg/kg daily.  Na2S was dosed more frequently because as a salt in aqueous 
solution, its H2S production is known to be short-lived, while the synthetic donors 
produce at least 24 hours of a stable H2S concentration in aqueous solution [12, 23].  
Total volume of each injection was 10 µL.  Control (breastfed) groups did not receive 
any intraperitoneal injections.  Doses are based on previous animal model studies of 
cardiac ischemia and reperfusion [15]. 
 
Clinical Assessment: 
          Control groups were assessed daily, while experimental groups were assessed 
with each feed.  Pups were assessed in a systematic fashion to ensure consistency.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
The clinical sickness score was previously published by Zani [21].  The reported clinical 
assessment score was the pup’s last score prior to death or euthanasia (Table 1). 
 
Perfusion Analysis: 
        Intestinal perfusion was analyzed transcutaneously with a Laser Doppler Perfusion 
Imager (LDI; Moor Instruments, Wilmington, DE).  As the laser was known to penetrate 
skin up to several millimeters thick, our previously published protocols were modified to 
allow for transcutaneous acquisition in the neonatal pups in order to avoid multiple 
surgeries [4].  Pups were held supine by their front limbs and tail and images were 
acquired of the entire torso and abdomen.  Using the computer software, a region of 
interest was created from the diaphragm to the pelvis to obtain a flux mean perfusion 
value within this region.  Full, visible bladders were excluded from the region of interest 
for consistency.  Perfusion was expressed as a percentage of baseline perfusion on P5.  
Pups that died during the protocol (1 in vehicle group, 1 in Na2S group, and 1 in AP39 
group) were included in evaluation with a perfusion value of 0%.  
 
Macroscopic Gut Assessment and Histology: 
          On P9, pups were sacrificed by decapitation and intestinal appearance was 
assessed with a macroscopic scoring system based on color, consistency, and dilation 
of the intestine as described by Zani et. al. (Table 2).  The terminal ileum and distal 
jejunum was then formalin fixed, paraffin embedded, and stained with hematoxylin and 
eosin.  Two blinded authors evaluated degree of injury by histology.  The histological 
scoring system used was published by Zani et. al [21] with scores ranging from 0 to 4.  
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0 = normal intestine; 1 = some disarrangement of villus enterocytes, villus-core 
separation; 2 = significant disarrangement of villus enterocytes, villus-core separation 
down sides of villi, blunting of villi; 3 = epithelial sloughing of villi, loss of villi; 4= 
necrosis.  A score of 2 or higher indicated presence of NEC, with 3 or higher indicating 
severe NEC.    
 
Intestinal Cytokine Analysis:  
          Murine organs were acquired and processed for proteins as previously described  
[4, 24, 25].  Following euthanasia, part of the small intestine, liver, and lung was snap 
frozen in liquid nitrogen and stored at -80°C.  Tissue was thawed and homogenized with 
the Bullet Blender (Next Advance, Averill Park, NY) in RIPA buffer (Sigma, St. Louis, 
MO) with 1:100 dilutions of both phosphatase and protease inhibitors (Sigma, St. Louis, 
MO).  After homogenization, samples were centrifuged at 12,000 rpm and supernatants 
were collected for further analysis.  Total protein was quantified with the Bradford Assay 
using a spectrophotometer (VersaMax microplate reader, Molecular Devices, 
Sunnyvale, CA).   
          Murine interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), interleukin 
1β (IL-1β), and interleukin 12 (IL-12) were measured using ELISA (R&D Systems, Bio-
Techne Corporation, Minneapolis, MN).  ELISAs were repeated to ensure consistency 
and values were normalized to the control group.  Assays were performed at 1:20 
dilution and cytokine concentrations were normalized to total protein for each sample. 
 
Statistical Analysis:  
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          Ordinal data was reported using median and interquartile range.  Continuous 
variables were reported as mean ± SEM.  All non-parametric data was compared using 
the Mann-Whitney U test.  GraphPad Prism 7 (GraphPad Software, La Jolla, CA) was 
used for all statistical analysis and figures.  P values less than 0.05 were considered 
statistically significant. 
 
 
RESULTS 
H2S improves weight gain and clinical status in experimental NEC. 
The breastfed group gained an average of 2.23 ± 0.10 grams over 4 days, while 
the PBS-treated NEC group averaged a gain of 0.01 ± 0.02 grams (p<0.0001).  
Although the overall weight gain was minimal, compared to the vehicle treated NEC 
group, each H2S-treated NEC group gained significantly more weight.  The GYY4137 
group gained 0.16 ± 0.03 grams (p=0.0007), the Na2S group gained 0.15 ± 0.05 grams 
(p=0.0142), and the AP39 group gained 0.09 ± 0.02 grams (p=0.0146, Figure 1A) 
Clinical assessment scores were significantly worse in the vehicle NEC group 
compared to the breastfed animals and improved in the H2S-treated groups (Figure 1B).    
While the median score in the control group was 0 (IQR=0-0), that of the vehicle NEC 
group was 3 (IQR=1.75-5.25, p=0.0001).  The median score for the H2S-treated NEC 
groups were lower: GYY4137: 1 (IQR=0-2, p=0.0109), Na2S: 1 (IQR=0-1, p=0.0027), 
and AP39: 1 (IQR=1-2, p=0.0185).   
 
H2S improves intestinal perfusion in experimental NEC. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
At P9, the mean perfusion of the breastfed group was 54.35% ± 5.28% of 
baseline on P5.  The vehicle group’s P9 perfusion was 24.16% ± 4.45% which was 
significantly lower than the control group (p=0.0015).  The H2S-treated NEC groups had 
higher perfusion than the vehicle NEC group (Figure 2).  At P9, perfusion of the 
GYY4137 group was 38.69% ± 2.03% (p=0.0079), Na2S was 46.95% ± 7.93% 
(p=0.0162), and the AP39 group was 37.48% ± 5.24% (p=0.0296).   
 
H2S reduces intestinal injury in experimental NEC. 
Median macroscopic injury score of the breastfed group was 0 (IQR=0-0) and 
that of the vehicle treated NEC group was 2.5 (IQR=2-3, p<0.0001).  The median score 
of the GYY4137 group was 1 (IQR=0-1, p<0.0001), the Na2S group was 0.5 (IQR=0-1, 
p<0.0001) and the AP39 group was 1 (IQR=0-2.25, p=0.0103, Figure 3A).  Histologic 
injury followed a similar pattern with a median score of 0.5 (IQR=0-1) for the breastfed 
pups and 2.5 (IQR=1.5-3) for vehicle-treated NEC pups (p<0.0001).  All 3 H2S-treated 
groups had improved histology compared to vehicle. The GYY4137 group’s median 
score was 1 (IQR=1-1.625, p=0.0011), the Na2S group’s was 0.5 (IQR=0.5-0.125, 
p=0.0004), and the AP39 group’s was 0.5 (IQR=0.5-1.125, p=0.0001).  Incidence of 
NEC in the Vehicle group was 70%, and it was 20%, 10%, and 0% in the GYY4137, 
Na2S, and AP39 groups respectively.  Severe NEC was present in 30% of the vehicle-
treated animals, and 0% of the H2S-treated animals (Figure 3B).     
 
H2S improves local inflammation in the intestine during experimental NEC. 
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Intestinal cytokines and growth factors were altered in the experimental NEC 
model.  Animals in the vehicle group had significant derangements in intestinal IL-6, 
VEGF, IL-1β and IL-12 compared to breastfed control (Figure 4).  IL-6, IL-1β and IL-12 
were all significantly decreased, while VEGF was increased in the vehicle treated NEC 
group. Treatment with each of the H2S donors brought these cytokines back toward 
control levels.   
 
H2S improves systemic inflammation during experimental NEC. 
Liver and lung cytokines and growth factors were also affected in the 
experimental NEC model with significant deviations in the vehicle group as compared to 
control (Figure 5).  In both lung and liver, IL-6, VEGF, and IL-1β were significantly 
reduced in the vehicle treated NEC group compared to control.  Only treatment with 
GYY4137 resulted in statistically significant improvements in IL-6 and VEGF in both the 
lung and liver. 
 
DISCUSSION 
Necrotizing enterocolitis is a devastating condition of the premature neonate that 
often requires extensive surgical resection of affected intestine for adequate treatment.  
Consequences of this disease result in high morbidity and mortality rates across this 
population.  A medical therapy that would reduce the need for surgical treatment is 
certainly needed.  Herein, we demonstrated that treatment with hydrogen sulfide 
(GYY4137, Na2S, and AP39) can provide protection in a mouse model of experimental 
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NEC by improving mesenteric perfusion, reducing mucosal injury, and by normalizing 
local and systemic cytokine and growth factor production.   
H2S has recently been appreciated as a gas mediator like carbon monoxide and 
nitric oxide.  Though it is synthesized endogenously from the amino acid cysteine, it can 
also be administered exogenously via an H2S donor.  H2S donor administration has 
been shown to be beneficial in experimental models of ischemic injury [4, 6, 15, 26, 27].  
Because NEC is mediated, at least in part, through intestinal ischemia and necrosis, 
H2S therapy may be of benefit in this situation as well.   
We noted an improvement in overall clinical status, including weight gain, in mice 
treated with H2S.  It is likely that these animals are not only healthier due to decreased 
systemic inflammation, but also may absorb nutrients more efficiently due to less 
diseased bowel.  It has previously been postulated that local and systemic inflammation 
during NEC is at least partly responsible for the known sequelae of weight loss and 
clinical deterioration in neonates [28].  
Improvement in intestinal perfusion was another observed benefit of H2S donor 
administration.  H2S is thought to modulate intestinal blood flow, in part as a direct 
intracellular messenger, but additionally through nitric oxide (NO) mediated effects [4].  
Both H2S and NO are potent smooth muscle relaxants, likely leading to vessel dilatation 
and improved mesenteric perfusion [29].  One of the possible mechanisms for this 
interaction involves H2S mediated upregulation of endothelial nitric oxide synthase 
(eNOS).  H2S has been shown to sulfhydrate critical cysteine residues on eNOS, 
thereby causing enzyme dimerization and upregulation of NO production [30].  Other 
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studies have demonstrated that eNOS is an integral intermediary in hydrogen sulfide’s 
ability to improve intestinal perfusion [4]. 
Bowel injury was also reduced both macroscopically and histologically compared 
to vehicle control.  While this is surely due in part to improved mesenteric perfusion, 
other beneficial actions of H2S may be at play as well.  Other targets of protein 
sulfhydration and modification include potassium channels, phosphatases, 
transcriptions factors, and other integral cell-signaling pathways [31, 32].  Sulfhydration 
can also directly protect proteins and preserve function by preventing oxidation at 
cysteine residues [33]. Additionally H2S has anti-apoptotic and anti-inflammatory 
properties, mediated through the NF-κB pathways [34].  These combined effects may 
have a direct effect on the intestinal epithelium outside of its effects on the mesenteric 
vasculature. 
The experimental NEC model also led to significant derangements in cytokines 
and growth factors in the intestine.  IL-6 was decreased in our NEC model, but returned 
to near breastfed control levels after the application of H2S donors.  Though IL-6 is 
usually thought of as pro-inflammatory, some studies have suggested that it plays a 
more protective role in the intestine and acts as an anti-inflammatory mediator.  This 
effect is likely mediated through its influence on other cytokines such as IL-1 [35].  One 
additional possibility is that by the time the tissue is harvested, the IL-6 has been 
exhausted from severe inflammation over multiple days.  Further investigation into IL-6’s 
role in intestinal ischemic injury is needed.   
VEGF is produced by endothelial cells in response to hypoxia or stress [18].  It 
was elevated in the vehicle group, but reduced by treatment with H2S donors.  This 
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would suggest that the endothelium was less stressed after administration of hydrogen 
sulfide donors. VEGF is also considered a growth factor and it plays a role in regulation 
of angiogenesis [19].  The results of this study might suggest that a higher level of 
angiogenesis was not necessary following H2S administration. 
IL-1β was consistently decreased in our NEC model, and returned to near normal 
levels with H2S treatment.  IL-1β is a secretory molecule that is released from 
macrophages.  It is typically pro-inflammatory, however, has not been shown to be 
elevated in NEC in previous studies [36].  It also plays a role in gut integrity and enteric 
mucosal protection by stimulating glial cells [37].  It therefore stands to reason that it 
may be reduced in experimental NEC, when the intestine is injured and gut barrier 
permeability is higher than baseline.   
IL-12 was decreased in the vehicle group, and increased toward baseline with 
H2S administration. IL-12 helps to promote the actions of interferon gamma and has 
been implicated as a factor in the onset of NEC and the progression toward fulminant 
disease [16].  Studies have demonstrated decreased IL-12 production in the intestinal 
epithelium in mice during experimental NEC [20].  This is consistent with our results, 
and improvement secondary to H2S administration is a positive indicator that the 
pathology was resolving. 
In the lung and liver tissue, similar patterns were noted in the vehicle treated 
NEC group compared to control with regard to IL-6 and IL-1β.  However, VEGF 
decreased in the vehicle group compared to control.  IL-12 was not evaluated in the 
liver and lung because it is thought to be more of an intestinal marker for NEC [20].  
Treatment with GYY4137 did result in an improvement in IL-6 and VEGF, but the rest of 
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the donors did not appear to facilitate a significant improvement in the systemic 
inflammatory response.   These data indicate that despite the improvement in intestinal 
injury that resulted from direct application to threatened bowel, the systemic effects of 
experimental NEC were likely not completely ameliorated by this therapy.  Further 
investigation into the effects of H2S on systemic inflammation is therefore warranted.   
 
LIMITATIONS 
Since the exact cause of NEC is not completely understood, we are limited in the 
types of animal models that are available for use.  As such, clinical correlation to human 
illness may be limited.  Although the clinical scores and intestinal perfusion parameters 
are strong indicators of the development of NEC, the diagnosis can only be established 
at postmortem evaluation of the intestine, and this makes it difficult to assess during the 
experiment whether or not NEC is being prevented.  Additionally, it is difficult to blind 
clinical assessments of the animals, as they were performed by the same person who 
administered the medication.  This was remedied by a very structured approach to 
clinical assessment, in addition to including more objective measures like intestinal 
perfusion and cytokine analysis.  All macroscopic and histologic evaluation was blinded, 
and corresponded with other clinical assessments.  
 
CONCLUSION 
H2S administration is beneficial in experimental NEC.  Mouse pups treated with 
H2S experienced only marginal weight gain, but did exhibit improved clinical status, 
increased intestinal perfusion, reduced intestinal injury, and normalization of 
inflammatory markers as compared to vehicle.  Further experimentation into 
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mechanism, mode of delivery, and adverse effects is necessary prior to widespread 
therapeutic use.  
 
FIGURE LEGENDS 
 
Figure 1: H2S improves weight gain and clinical status in experimental NEC.  A) The 
vehicle group had virtually no weight gain compared to control, and though the H2S 
groups had very minimal, it was statistically better than the vehicle group.  B) Clinical 
assessment scores were higher (worse) in the vehicle group compared to control, and 
improved in the H2S-treated groups.  Transverse bars represent median clinical score 
and each symbol represents an individual pup’s score.  (*: p<0.05 vs. breastfed, #: 
p<0.05 vs. vehicle) 
 
Figure 2: H2S improves intestinal perfusion in NEC as measured by LDI compared to 
vehicle.  A) Perfusion on P9 is reported as a percentage of baseline perfusion on P5.  
Perfusion was significantly lower in the vehicle group and improved in all three H2S-
treated groups. (*: p<0.05 vs. breastfed, #: p<0.05 vs. vehicle)  B) Representative 
pictures from LDI software of each group’s transcutaneous intestinal perfusion.  Red 
areas indicated higher perfusion, and blue areas indicated lower levels of perfusion.  
The left side of each image is the pelvis and the right is the diaphragm.   
 
Figure 3: H2S reduces intestinal injury in NEC compared to vehicle.  A) Macroscopic 
injury score was higher (worse) in the vehicle group as compared to the breastfed 
animals.  All three H2S-treated groups had improved scores.  B) Histologic injury scores 
were higher (worse) in the vehicle group compared to the breastfed group.  All three 
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H2S-treated groups had improved scores. (*: p<0.05 vs. breastfed, #: p<0.05 vs. 
vehicle)  C) Representative sections from each treatment group (H&E stain, 20x). 
 
Figure 4: H2S normalizes intestinal inflammation in NEC compared to vehicle.  The 
vehicle group had significantly decreased IL-6, IL-1β, and IL-12 and increased VEGF 
compared to control.  Each H2S-treated group had levels closer to breastfed control 
indicating normalization in local inflammation. (*: p<0.05 vs. breastfed, #: p<0.05 vs. 
vehicle) 
 
Figure 5: H2S normalizes systemic inflammatory response in NEC compared to vehicle.  
The vehicle group had significantly decreased IL-6, VEGF, and IL-1β compared to 
control.  H2S treatment may have facilitated some normalization back to breastfed 
control levels, however this was not a statistically significant difference, with the 
exception of the GYY4137 group for IL-6 and VEGF.  (*: p<0.05 vs. breastfed, #: p<0.05 
vs. vehicle) 
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Table 1. Clinical Assessment Score  
Appearance 
0 Tonic and well-hydrated, glossy skin 
1 Slimmer, with visible skin folds 
2 Skinny, dehydrated 
3 Gasping, in agony 
Natural Activity 
0 Moving normally in the cage 
1 Wriggles if put supine 
2 Does not wriggle if put supine 
3 Not moving limbs, lying still, supine or lateral 
decubitus 
Response to Touch 
0 Alert without any stimulation 
1 Responding to mild stimulation (gentle foot touch) 
2 Responding to vigorous stimulation (foot pinch) 
3 Unresponsive to vigorous stimulation (does not 
become alert when picked up and moved) 
Body Color 
0 Pink 
1 Pale or dark distal extremities, fingers/toes 
2 Pale whole body 
3 Grey 
Zani et. al. 2008 
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Table 2. Macroscopic Gut Assessment Score  
Consistency 
0 Normal, does not tear when dissecting from 
surrounding tissue 
1 Moderately friable 
2 Liquefied, jelly-like, extremely friable 
Color 
0 Normal, yellow/tan 
1 Patchy discoloration, pink, congested 
2 Extensive discoloration, dark, necrotic 
Dilation 
0 Normal, no dilation 
1 Patchy areas of dilation 
2 Extensive dilation throughout small bowel 
Zani et. al. 2008 
